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INTRODUCTION 
 
 Intra Venous Regional Anesthesia is a safe and effective technique 
for providing anesthesia as well as bloodless field during hand surgery. 
Traditionally, an upperarm tourniquet has been used for these procedures. 
However, upperarm IVRA does have some disadvantages including the 
potential for local anesthetic toxicity, Tourniquet pain and lack of 
postoperative analgesia. Toxicity may be caused by leakage past the 
tourniquet because of high venous pressures or tourniquet failure. Adverse 
reactions have also been reported upon tourniquet release, especially when 
larger doses of local anesthetic are used. 
 
 The application of a Forearm tourniquet offers several advantages to 
the use of an upperarm tourniquet. Forearm IVRA allows the dose of LA to 
be decreased by upto 50 %, without affecting the quality of analgesia. In 
addition, the forearm tourniquet can be tolerated longer and was consistently 
rated less painful when compared with the upperarm tourniquet. Finally, 
using a forearm tourniquet allows for preservation of some motor function 
of the long flexors and extensors of the wrist and hand which is useful in 
certain operations such as Tenolysis and fixation of hand fractures.  
  
 
 The routine use of a forearm tourniquet has previously been avoided 
because of the potential risk of nerve injury, incomplete hemostasis and 
leakage of local anesthetic into the systemic circulation. However, these 
theoretical concerns have not been substantiated in any studies. Several 
investigations revealed that the forearm tourniquet is a safe and effective 
technique for hand surgery. In fact, the use of a forearm tourniquet may be a 
safer alternative to upperarm IVRA by reducing the local anesthetic dosages 
to nontoxic levels.    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
AIM OF THE STUDY 
 
      To evaluate the efficacy of forearm tourniquet, in 
comparison with upperarm tourniquet in Intra Venous Regional 
Anesthesia on the  quality of the block and the post operative pain 
relief. 
 
  
 
HISTORY 
 
Intra Venous Regional Anesthesia was first described by August Bier 
in 1908. He described a method of “venous anesthesia” in 134 patients with 
good anesthesia and no “bad effect”  He observed that when local anesthetic 
was injected intravenously, between two tourniquets on a limb a rapid onset 
of anesthesia occurred in the area between the tourniquets and a slower 
onset occurred beyond the distal tourniquet. 
Adams, in a 1944 review article, cited Bier as well as Alms, who in 
1886 had described intravenous injection of local anesthetic with subsequent 
analgesia in the area of the body drained by the vein. The technique was 
reintroduced and slightly modified by Holmes in 1936, using either a single 
or a double tourniquet at one site and injecting local anesthetic as distal as 
possible to the cuff. Since then many reports have touted its simplicity and 
benefits. 
Reuban et al and Steinberg stated that IVRA with forearm tourniquet 
provided an enhanced postoperative analgesic effect when compared with 
an upperarm tourniquet. 
 
 
 
  
INTRA VENOUS REGIONAL ANESTHESIA 
 
 Intra Venous Regional Anesthesia is technically simple and does not 
require specific anatomical knowledge. Success rate is 96-100% with a low 
incidence of side effects. It is a reliable, simple and safe method of 
providing anesthesia for minor surgical procedures of the extremities, if 
administered by experienced clinicians.  
Mechanism of Action: 
 Local anesthetic diffuses into the small veins surrounding the nerves 
and then into the vasa nervorum and capillary plexus of the nerves, leading 
to core of mantle (centrifugal) conduction block in the nerves involved local 
anesthetic then diffuses into the small nerves in the skin, blocking their 
conduction. The tourniquet produces ischaemia, which contributes to the 
analgesic action of the local anesthetic by blocking, nerve conduction and 
motor end plate function twenty minutes after tourniquet application alone 
there will be analgesia to pinprick without injection of any local anesthetic. 
However, the speed of onset and density of anesthesia are greater with 
injection of local anesthetic. 
Site of action: 
     Carbon 14 labelled 1%Lignocaine readily permeates tissues by direct 
migration through the walls of vascular beds. Support for the view that 
anesthetics act on the nerve trunks, comes from intravenous injection of 
  
radiopaque dyes and the observation that the more distal parts of the 
extremity are innervated by the core fibres of the nerve trunk. Since the core 
is well supplied with abundant vascular channels that could carry the 
anesthetic to the core fibres, the more distal parts of the extremity should 
become anesthetized first as has been noted clinically.  Impulse transmission 
studies indicate that the site of action is at the branching points of the nerve 
fibres. 
PROCEDURE: 
 
QUALIFICATIONS OF THE PERSON ADMINISTERING IVRA: 
  
          Local anesthetics can cause serious morbidity and mortality in small 
amounts through allergic reactions and in the large amounts used in IVRA 
by direct toxic effects on the brain and heart. So the person administering 
the anesthetic must be trained and qualified to handle convulsions, 
respiratory arrest, myocardial depression and cardiac arrhythmia and arrest 
decisively and appropriately. A current ACLS or comparable certification, a 
facility with rapid endotracheal intubation and artificial ventilation and 
familiarity with cardiac arrest and seizure treatment protocols should be the 
minimal acceptable  qualification. 
 
 
 
  
Advantages: 
¾ Speed of onset and rapid recovery 
¾ Reliability (in the absence of local infection and with adequate 
equipment) 
¾ Muscle relaxation 
¾ Technical simplicity 
Disadvantages and Complications: 
¾ Poor post operative analgesia 
¾ Limited time of surgical anesthesia (<90 minutes) 
¾ The potential of systemic local anesthetic toxicity 
¾ Nerve damage secondary to direct compression by the tourniquet 
¾ Compartment syndrome and loss of limb (very rare)  
INDICATIONS: 
 IVRA is used for surgical interventions on the hand, forearm or elbow 
that will not exceed 1 hour. These include manipulation of forearm 
fractures, excision of ganglion, palmar faciotomy, debriding wounds, 
removing foreign bodies, wrist and ankle arthroscopy, carpal tunnel 
decompression, repair of ruptured tendons, incision and drainage of 
abcesses and paronychia, podiatric surgery, microsurgical repair of limbs, 
suturing extensive lacerations that would otherwise require a large  and 
  
possibly toxic dose of local anesthetic infiltrated into the wound edges, 
excision of painful scars and grafting. 
CONTRAINDICATIONS: 
     Contraindications are mainly related to tourniquet use. Absolute 
contraindications include sickle cell disease, Raynaud’s disease or 
scleroderma, allergy to local anesthetics and patient refusal. Relative 
contraindications include severe hypertensive or peripheral vascular disease, 
local infection and skeletal muscle disorder or pagets disease where local 
anesthetic may spread to the systemic circulation via venous channels in 
bone, patients who are unable to cooperate because of psychosis and 
dementia, progressive neurologic disease, coagulation disorders, and 
patients with calcified peripheral arteries.  
The equipment required for IVRA includes: 
 Pneumatic tourniquet (checked for leaks before the procedure) and a 
pressure gauge. 
 Esmarch bandage or Rhys-Davis exsanguinator  
 Local anaesthetic solution 
 Resuscitation equipment and drugs. 
Intra Venous Regional Anesthesia  of the arm: 
 A 22 G cannula is placed intravenously as distal as possible in the 
arm to be anaesthetized. Venous access is established in the opposite arm to 
  
allow administration of fluids or drugs if necessary. The double tourniquet 
(two tourniquets each 6 cm wide) or a single one (14 cm wide) is applied on 
the arm with generous layers of padding, ensuring that no wrinkles are 
formed and the tourniquet edges do not touch the skin. The arm is 
exsanguinated either by using the Esmarch bandage or a Rhys-Davis 
exsanguinator. If this is impossible, exsanguination can be achieved by 
elevating the arm for 2-3 minutes while compressing the axillary artery. The 
distal tourniquet is inflated to at least 100mgHg higher than the patient’s 
systolic blood pressure (250-300mmHg). The proximal tourniquet is inflated 
to the same pressure. After ensuring inflation, the distal cuff is deflated. 
 
 Before injecting local anaesthetic it must be confirmed that no radial 
pulse is palpable. The local anaesthetic is then injected slowly. A standard 
volume for injection into the upper limb is 40ml, which can be increased to 
50ml in a fit, large adult. If the injection is too rapid, the venous pressure 
may exceed the tourniquet pressure and the local anaesthetic solution may 
escape into the systemic circulation. Surgical Anesthesia is usually achieved 
within 15 minutes. The distal tourniquet, which overlies part of the 
anaesthetized arm, can then be inflated and the proximal one deflated to 
relieve tourniquet pain. 
 The cuff should not be deflated until 20 minutes after local 
anaesthetic injection because systemic toxic doses of local anaesthetic may 
  
occur. After 20 minutes, 30% of the injected drug is fixed within the tissues 
and is unavailable for immediate release into the systemic circulation. Cuff 
deflation should be performed in cycles with deflation / inflation times of 
less than 10 seconds until the patient no longer exhibits signs of systemic 
toxicity (e.g. tingling of the lips, tinnitus, drowsiness). Severe signs of 
systemic toxicity include bradycardia, hypotension, ECG abnormalities, 
seizures and loss of consciousness. Maximum blood levels of local 
Anesthesia occur within 10 minutes of cuff deflation. Therefore, the patient 
should be monitored closely for 30 minutes following tourniquet release.  
Ten minutes after cuff deflation, blood levels will be less than 2 
micrograms/ml, when Lignocaine is used in a dose of 2.5 – 3 mg/kg. 
 
 If severe CNS intoxication occurs, appropriate resuscitation 
guidelines should be followed. Emergency drugs must be readily available 
and 100% oxygen should be administered. 
Forearm Intra Venous Regional Anesthesia: 
 Forearm IVRA has been infrequently used in the past because of 
concerns of local anesthetic leakage, difficulty maintaining a bloodless field, 
and possible nerve injury. It was thought that “compression forces of an 
inflated forearm tourniquet cannot obliterate the anterior and posterior 
interosseous arteries seated in the deep ‘valley’ between the prominent 
  
radius and ulna”. It was therefore assumed that tourniquet leakage was 
inevitable. 
 In addition, concern was expressed that the distal part of the limb is 
too small to withstand the higher localized pressures with the use of a 
forearm tourniquet. It has also been suggested that proximal tourniquet 
placement is more likely to transfix the ulnar nerve, resulting in an increased 
incidence of traction neuritis. 
 
 However, these theoretical concerns have not been substantiated in 
any studies. In fact, several studies revealed that the forearm tourniquet is a 
safe and effective technique for hand surgery. A review of more than 1000 
patients undergoing surgery using a forearm tourniquet resulted no 
significant increases in the incidence of peripheral nerve injury. 
 Furthermore, adequate intraoperative analgesia occurred in all 
subjects using fifty percent less Lignocaine than normally used for IVRA. 
Forearm IVRA provides significant postoperative analgesia benefit. The 
reason for this enhanced analgesic effect is not known. One possible 
explanation may be an increased binding of analgesics to the local tissues 
during forearm IVRA. The prolonged sensory block observed in the forearm 
IVRA is clinically useful to surgeons at the end of the operative procedure. 
Because recovery of pain sensation is rapid after tourniquet deflation with 
upperarm IVRA, subsequent hemostasis and wound closure may be difficult 
  
to achieve. So surgeons recommend routine wound infiltration or 
metacarpal block immediately before tourniquet deflation. Because forearm 
IVRA provides  prolonged sensory analgesia, it may reduce or eliminate this 
need to supplement the IVRA. 
 Forearm IVRA not only provides enhanced postoperative analgesia, 
but also increases the safety margin of this technique. This allows for a 50% 
reduction in the dose of Lignocaine, therefore this approach reduces the risk 
of local anesthetic toxicity in the event of tourniquet failure. 
Duration of effective analgesia: 
     Usually about 45 minutes after, tourniquet inflation, discomfort becomes 
bothersome. The anesthetist can then inflate the distal tourniquet and when 
assured that satisfactory occlusion pressure for that tourniquet plus 
100mmHg is present and stable in the cuff, deflation of the proximal 
tourniquet is done. This will give some relief and allow another 15 to 
30minutes before tourniquet pain again becomes relatively bothersome. 
     Continued switching from proximal and distal tourniquet and vicecresa, 
will allow often another half hour pain free IVRA. Judicious use of small 
doses of intravenous sedatives, anxiolytics and narcotics will also contribute 
to extending the time the tourniquet will be tolerated. If the surgical 
procedure extends beyond 1.5 hours a light general anesthesia such as 
nitrous oxide and oxygen is almost always necessary. The effectiveness of 
  
the anesthetic can be markedly enhanced by inflating the tourniquet 10-20 
minutes prior to injecting the anesthetic. Only half the dose of the anesthetic 
is needed for satisfactory analgesia if this is done. 
TOURNIQUET RELEASE: 
     If surgery has lasted less than 30minutes, it is suggested that the 
tourniquet be deflated for only 15 seconds and reinnflated for 30 seconds to 
2minutes and this cycle be repeated several times before the cuff is let down 
permanently. If the tourniquet has been inflated for over 30 minutes it is 
generally safe to let the tourniquet down all at once. During the procedure 
there is a constant leakage of anesthetic out of the extremity, via 
intramedullary bone channels and after 30 minutes a nontoxic amount of 
anesthetic remain in the extremity. Some sources have shown that it is safe 
to deflate the tourniquet all at once even if the surgery has taken as little as 
5-15 minutes. 
REINJECTION: 
     After the tourniquet is deflated and the anesthetic is deflated and the 
released into the general circulation, the lungs act as a giant reservoir and 
clear a large amount of anesthetic as it passes through them, releasing it 
over subsequent circulation times. Peak levels of the anesthetic are 20-80% 
less than if the same amount of local anesthetic had been given i.v. 
Approximately 30% of the drug is released from the extremity at first and 
  
50% still remain in the arm after 30 minutes. It is possible to reinject one 
half of the original dose, 30 minutes after tourniquet release and to achieve 
adequate analgesia for an additional 30 -45 minutes of surgery without 
raising the intravascular anesthetic concentration. 
Intra Venous Regional Anesthesia of the leg: 
 The basic technique is the same as for the arm but the dose and 
volume of local anaesthetic has to be doubled for IVRA of the leg, which is 
associated with an increased potential for local anaesthetic toxicity. The 
tourniquet pressure must be higher in the leg (350-400mmHg), to occlude 
blood flow in the femoral artery. This may increase the occurrence of 
tourniquet pain. Tourniquet may be applied to the thigh (two tourniquets 
about 9 cm wide) or one at the calf (below the head of the fibula) and one at 
the thigh. The latter is for safety in case of distal cuff failure and is not 
usually inflated. 
 Choice of drugs 
 Many local anaesthetic drugs, with or without additives, have been 
used for IVRA, but 0.5% prilocaine, 3-6 mg/kg, is the drug of choice, 
because it has less systemic toxicity and is partially taken up in the lungs 
before reaching the systemic circulation. The usual dose is 40ml (200mg) 
without epinephrine. However, the manufacturers have ceased production of 
0.5% prilocaine. 1% prilocaine remains available and is licensed for IVRA, 
  
though its stability is not guaranteed if diluted. If prilocaine is unavailable 
and 0.5% Lignocaine, 3 mg/kg, is used. If IVRA is applied to the leg a 
larger volume must be injected (upto 100 ml). Prilocaine can be used 
undiluted (maximum recommended dose is 400mg in adults) but Lignocaine 
is commonly diluted to lower concentrations (e.g. 0.2-0.25%) 
 Prilocaine can cause methaemoglobinaemia but unless doses in 
excess of 600 mg are used, it is clinically insignificant in most patients. 
Although one has to be aware that in patients with anaemia or cardiac 
conditions even small amounts of methamoglobin can significantly impair 
the oxygen carrying capacity of their red blood cells. Intravenous regional 
Anesthesia with prilocaine in these patients should be considered carefully 
for its benefits. 
 Other local anaesthetic agents have been used but do not provide 
superior analgesia or more rapid onset of block. Severe toxic reactions and 
death have been observed with bupivacaine and its use is contraindicated. In 
one study, 0.2% ropivacaine used intraoperatively was as effective as 0.5% 
prilocaine, but postoperative analgesia was prolonged; 
 Additives to local anaesthetics have not been consistently shown to 
have an effect during IVRA but may increase the length of postoperative 
analgesia, probably because of a systemic effect following tourniquet 
  
release. The reported enhancement of IVRA with pethidine, 1 mg/kg, may 
reflect intrinsic local anaesthetic activity of the drug. 
 Experiments with the addition of muscle relaxants produced marked 
muscle relaxation but did not augment analgesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TOURNIQUETS 
 Operations on the extremities are made by the use of a tourniquet. A 
pneumatic tourniquet is safer than Esmarch tourniquet or the Martin sheet 
rubber bandage. A pneumatic tourniquet with a hand pump and a pressure 
gauge is probably the safest, but a constantly regulated pressure tourniquet 
is quite satisfactory. Sphygmomanometer cuff when used, must be wrapped 
with a gauze bandage to prevent slipping. 
 
 The extremity is then elevated for two minutes or the blood is 
expressed by a sterile sheet rubber bandage or a cotton elastic bandage. 
Beginning at the fingertips or toes, the extremity is wrapped proximally to 
within 2.5-5cm of the tourniquet. The tourniquet should be inflated quickly 
to prevent filling of the superficial veins before the arterial blood flow has 
been occluded. 
TOURNIQUET PRESSURES: 
 Reid, Camp and Jacob used pneumatic tourniquet pressures 
determined by the pressure required to obliterate the peripheral pulse using a 
Doppler stethoscope; they then added 50-75mmHg to allow for collateral 
circulation and blood pressure changes. Tourniquet pressures from 135-
255mmHg for the upper extremity and 175-305mmHg for the lower 
extremity were satisfactory. 
 
  
 Esterson and Sourfman recommended pressures of 90-100mmHg 
above the pre operative systolic arm blood pressure. Others have 
recommended 50-75mmHg above the systolic blood pressure for the surgery 
in the upper extremity and 100-150mmHg for surgery in the lower 
extremity. 
 According to Crenshaw et al, wide cuffs are more effective at lower 
inflation pressures than are narrow one. Any solution applied to the skin 
must not be allowed to run beneath the tourniquet or a chemical burn may 
result. 
TOURNIQUET TIME: 
 There is no rule as to how long a tourniquet may be safely inflated. 
The time may vary with the age of the patient the vascular supply of the 
extremity. In an average healthy adult, the author prefers to leave the 
tourniquet inflated no more than 2 hours. If an operation on the lower 
extremity takes longer than 2 hours, it is better to finish it as soon as 
possible. Alternatively the tourniquet can be deflated for ten minutes and 
reinflated again.  If the tourniquet is absolutely essential and when the 
advantages justify the risk for lengthier procedure, tourniquet must be 
deflated atleast for 20 minutes to restore normal oxygenation, pH, chemistry 
of the limb. TT may be extended to 3 hours if tourniquet is deflated for 20 
minutes at the end of each hour. But this usually interferes with the 
  
operative procedure. So it is wiser to proceed with the tourniquet for two 
hours and then discontinue its use. 
FOREARM TOURNIQUET: 
 Khuri and co workers found in a prospective study that applying a 
tourniquet to the forearm is safe and effective for surgery of the hand and 
wrist.  They are safe, effective and well tolerated for surgery in the dlistal 
forearm, wrist and hand. The optimal tourniquet pressure for this technique 
is 75-100mmHg above the patients systolic blood pressure.  
Wrap several layers of soft cost padding circumferentially around the 
proximal forearm and apply a pneumatic tourniquet approximately 5 cm 
below the medial condyle.  
TOURNIQUET PARALYSIS: 
 It can result from  
(1) Excessive pressure 
(2) Insufficient pressure resulting in passive congestion of the part with 
hemorrhagic infiltration of the nerve 
(3) Keeping the tourniquet for too long 
(4) Application without consideration of local anatomy. 
POST TOURNIQUET SYNDROME: 
 It is a common reaction to ischemia and is characterized by edema, 
pallor, joint stiffness, motor weakness and subjective numbness. This is due 
  
to duration of ischemia and not to mechanical effect of tourniquet. Post 
tourniquet syndrome interferes with early motion and results in increased 
narcotic requirements. Spontaneous resolution occurs in one week 
TOURNIQUET HYPERTENSION AND TOURNIQUET PAIN: 
 Differential blockade of some fibres but not others may explain the 
occurrence of Tourniquet Hypertension, despite adequate sensory level by 
pinprick. Tourniquet pain is mediated by unmyelinated slow conducting ‘c’ 
fibres and gate theory mechanism of large fibre block and small fibre 
activity. 
 
 Recommendation to ameliorate tourniquet pain is to use subarachnoid 
blockade than General Anesthesia or Epidural Anesthesia. Obtain adequate 
pin prick level. Epinephrine, clonidine, but not glucose can be added as 
adjuvants to decrease the tourniquet pain. 
 
 
 
 
 
 
 
 
  
PHARMACOLOGY OF LIGNOCAINE 
 
 Lignocaine is a synthetic amide linked anaesthetic of intermediate 
potency and duration. In 1943 Lofgren synthesized Lignocaine in Sweden. 
First used by Gordh in 1948. 
 
Lignocaine is the standard to which all other local anaesthetics are 
compared. It is currently the most widely used local anaesthetic. In addition, 
it is popular antiarrythmic. It an be given by almost any route. 
 
Mechanism of action: 
 Lignocaine prevent transmission of nerve impulses by inhibiting 
passage of sodium ions though ion-selective sodium channels in the nerve 
membranes. This slows the rate of depolarization such that the threshold 
potential is not reached and thus action potential is not propagated. But 
resting membrane potential is not altered. Lignocaine binds to the inner 
portion receptor (i.e. Sodium channel) after entering the cell membrane. 
Physiochemical properties: 
 Molecular weight 234 
 Weak base with a pka 7.6 – 7.8 
 Very stable, not decomposed by boiling, acids or alkalies  
 It is less lipid soluble than that of Bupivacaine 
 
  
Pharmacokinetics: 
Absorption: 
 It is absorbed from the site of application or injection into the blood 
stream. Rate of absorption depends on the blood flow to the area and use of 
epinephrine. 
Metabolism: 
 Metabolized in liver by oxidative dealkylation to monoethylglycine 
xylidide followed by hydrolysis of this metabolite to xylidide. Metabolism 
is dependent on hepatic blood flow. 
 
 Monoethylglycine xylidide has 80% activity of the parent drug. 
 
 Xylidide has 10% activity of the parent drug. 
 
 75% of xylidide is excreted in the urine as 4-hydroxyl-2, 6-
dimethylaniline. 
Onset of action: 
 Rapid onset of action. 
¾ Topical Anesthesia 5-10 mins 
¾ Conduction Anesthesia 
For small nerves 5-10 mins 
For large nerves 10-15 mins 
¾ Intravenous administration 1-2 mins 
  
Protein binding: 
 It is 70% bound to α 1 acid glycoproteins  
Volume of distribution: 
 91 litres 
Distribution: 
 Lignocaine has a triphasic distribution 
Rapid distribution phase (α): 
 In this phase, the drug is distributed to highly vascular regions.        
t½  α is 1 min. 
Slow disappearance phase (β): 
 The drug is distributed to slowly equilibrating tissues. 
 t½ β is 9.6 min.  
Slow transformation and excretion phase (δ): 
 t½ is δ is 1.6 hrs.  
 Clearance is 0.95 litres per minute 
Availability: 
a. 5% heavy 2ml ampoules which contain 50 mg of Lignocaine / ml 
with 75mg – 100 mg of dextrose. 
b. 2% ligocacine (xylocard) without preservative – 50 ml vial for 
intravenous use 
  
c. 2% Lignocaine – plain – 30 ml vial – contains methyl and propyl 
paraben as preservative. 
d. 4% Lignocaine with 1 in 200000 Adrenaline – 30 ml vial. 
e. 4% Lignocaine viscus 
f. 4% Lignocaine aqueous solution 
g. 10% Lignocaine spray 
h. 2% Lignocaine jelly 
i. 2% Lignocaine ointment 
j. 5% Lignocaine ointment 
Pharmacodynamics: 
Local actions: 
 Causes nerve blockade with loss of pain and temperature sensation 
touch, motor power and vasomotor tone in the region supplied by the nerves 
blocked. 
Systemic actions: 
 Result of systemic absorption from the site of administration or 
intravenous administration.  
Cardiovascular system: 
 It has a stabilizing effect on the cell membranes of cardiac tissue. 
  
 Lignocaine, depresses myocardial automaticity by antagonizing the 
spontaneous phase IV depolarization and reduces the duration of effective 
refractory period. 
 Myocardial contractility and conduction velocity are depressed at 
higher concentrations. 
 These effects result from direct cardiac muscle membrane changes 
(i.e.) cardiac sodium channel blockade. 
 It stabilizes the membrane of damaged and excitable cells, tending to 
suppress ectopic foci. 
Respiratory system: 
 Lignocaine depresses hypoxic drive (the ventilatory response to low 
PaO2)    
 Apnea can result from phrenic and intercostals nerve paralysis or 
depression of the medullary respiratory center following direct exposure to 
the local anaesthetic agents. 
 Relax bronchial smooth muscle. 
 Intravenous Lignocaine may be effective in blocking the reflex 
bronchoconstriction associated with intubation. 
Vascular smooth muscle: 
 Produces vasodilatation 
 
  
Central nervous system: 
 Produces a sequence of stimulation followed by depression. Produces 
sedation on intravenous administration.  
 Intravenous administration decreases cerebral blood flow and 
attenuates the rise in intracranial pressure that accompanies intubation. 
 Infusion of Lignocaine is capable of reducing the MAC of volatile 
anaesthetics by 40%. 
Musculoskeletal:    
 Lignocaine is myotoxic leading to lytic degeneration, edema and 
necrosis. 
Haematological: 
 It decreases coagulation and enhances fibrinolysis. 
Indications: 
1. For infiltration block, peripheral nerve blocks, epidural, spinal and 
topical anaesthetia & intravenous regional Anesthesia. 
2. Antiarrythmic 
Lignocaine is a class IB antiarrythmic 
 Ventricular tachyarrythmias 
 Arrythmias following acute MI during cardiac surgery 
 In digitalis toxicity – because it does not worsen AV – block 
  
3. Prevention or treatment of increases in intracranial pressure during 
intubation 
- antitussive effect may be the reason. 
 
4. Reflex induced bronchospasm is also attenuated by IV administration 
of Lignocaine. 
5. Suppresses noxious reflexes such as coughing & sympathetic 
stimulations associated with endotracheal suctioning and intubation. 
6. Used as an antiepileptic agent intravenously  
7. Used intravenously as an analgesic for certain chronic pain states 
8. Used as a supplement to general anaetheisa 
Contraindications: 
¾ Hypersensitivity  
¾ Should not be used with vasoconstrictor in digits of hand, feet 
and penis. 
¾ Stokes Adams syndrome, severe degree of heart block 
Doses: 
Maximum recommended dose: 
a) Plain    - 3mg/kg  
b) With adrenaline  - 7 mg/kg 
c) For reflex suppression - 1.5 mg/kg iv. 
 
  
Drug interactions:    β Blockers:  
 Coadministration of Betablockers, increases serum levels of 
Lignocaine and its toxicity by decreasing Lignocaine’s metabolism. 
Anticonvulsant agents: 
 Increases Lignocaine’s metabolism 
Non depolarizing muscle relaxant 
 Blockade is potentiated by Lignocaine 
Opioids and α2 adrenergic agonists: 
 Potentiate Lignocaine’s pain relief. 
Antiarrythmic agents: 
 Potentiate the cardiac effects of Lignocaine 
Toxicity: 
¾ Mostly due to systemic absorption of locally administered Lignocaine 
or due to accidental intravenous administration of large doses of 
Lignocaine. 
¾ The central nervous system is mostly vulnerable. 
Blood levels and symptoms: 
 4 μg/ml : Light  headedness, tinnitus, circumoral and tongue 
numbness (anticonvulsant and antiarrhythmic activity) 
 6 μg/ml : visual disturbances 
 10 μg/ml : convulsions 
  
 12 μg/ml : Unconsciousness 
 15 μg/ml : Coma 
 20 μg/ml : respiratory arrest 
 26 μg/ml : cardiovascular collapse 
Treatment of toxicity: 
 Continuous monitoring of CVS and RS status helps to identify the 
toxicity earlier. 
 If convulsions occur barbiturates or benzodiazepines can be given. 
 Succinylcholine 1 mg/kg to paralyse the patient and aids in 
controlling the seizures. 
 Cardiac toxicity like ventricular fibrillation can be treated by 
defibrillation 
 Ventilatory support – 100% oxygenation, intubation, etc., 
 Maintain B.P. by rapid infusion of I.V. fluids, use of vasopressors and 
put the patient in Trendelenberg’s position. 
 Maintain fluid and electrolyte balance. 
Adverse effects: 
1. Allergic and hypersensitivity reactions 
Due to the preservative used – methyparaben  
2. CVS: 
Bradycardia, hypotension 
  
REVIEW OF LITERATURE 
 
 
2)  An evaluation of the analgesic efficiency of Intra Venous Regional 
Anesthesia using a forearm versus upperarm tourniquet. Department of 
Anesthesiology, Baystate medical center and Tufts University school of 
medicine, Springfield, Massachusetts. Anesthesia Analgesia 2002:95; 
457-460. This prospective, randomized study was conducted in forty 
patients scheduled for hand surgery. The authors have concluded that 
forearm IVRA provides for both a longer duration of sensory block and 
prolonged postoperative analgesia compared with conventional upperarm 
IVRA. The technique is safer because it allows for a 50% reduction in 
the dose of Lidocaine. 
 
3) Decreasing the toxic potential of IVRA Department of Anesthesia, 
Maisonnevve-Rosemont Hospital, Montreal. Canadial journal of 
Anesthesia 1989; 36:498-502. 
In this study the volume of the forearm venous system was 
predetermined angiographically IVRA with three solution of lignocaine 
0.25%, 0.355% and 0.5% was administered in a volume equal to the 
forearm venous system.  Angiographic results indicated that a forearm 
tourniquet provides adequate vascular isolation. 
  
The authors have concluded that Lidocaine 0.5% resulted in a dose of 
1.5 mg/ kg and provided excellent analgesia, and the use of forearm 
tourniquet allows reduction of the local anesthetic dose to a non-toxic 
level and thus increases the safety of IVRA. 
 
4) Results of IVRA with distal forearm application. Ankara Training and 
Research Hospital, Turkey. Acta Orthop Belg 2004, 70,401-405. 
 In this study, 120 patients were operated under clistal forearm IVRA (3 
cm above the wrist) using a 10 ml of local anesthetic solution. They 
have concluded that distal forearm IVRA proves safe, rapid and 
effective anesthesia. 
 
5) IVRA with a forearm tourniquet CJA 1987, 34: 21. The authors have 
concluded that IVRA with a forearm tourniquet provides successful 
analgesia with prolonged postoperative analgesia, when 0.5% 
Lignocaine used in a dose of 2 mg/kg 
 
6) Quantitative comparison of leakage under the tourniquet in forearm 
versus conventional IVRA. Department of Anesthesia and Division of 
nuclear medicine, Toronto-Canada. Anest-Anal 1999; 49-148. 
  
This prospective randomized trial was conducted on 14 healthy 
volunteers using Radiolabeled 99M Tc-Disofenin which structurally 
resembles lignocaine. The volume used was 0.6 ml/kg to a maximum of 
45ml for the upperarm IVRA and 0.4ml/kg to a maximum of 25ml for 
the forearm. Radioactivity was recorded in the limb at 30 sec intervals 
for 20 min post tourniquet deflation. They have concluded that leakage 
under the tourniquet from forearm and upperarm IVRA is similar. A 
larger bolus of drug enters the circulation on tourniquet release in 
upperarm IVRA than in forearm IVRA both at 3 and 20 min deflation. 
 
6.   Efficacy of forearm versus upperarm tourniquet for local anesthetic 
      surgery of the hand. Journal of hand surgery volume 25 No. 6; 573-74. 
This prospective study done in 100 consequetive patients with an 
upperarm tourniquet were compared with 100 consecutive patients, with 
a forearm tourniquet. They have concluded scoring of perceived pain 
was not significantly different in the two groups. Fore arm tourniquet 
was well tolerated and was not associated with complications. 
 
7.  Comparison of anesthetic effect between 0.375% ropivacaine versus  
0.5% Lignocaine in forerm IVRA. Regional anesthesia pain medicine   
2002 Nov-Dec; 27(6) 595-599. 0.375%ropivacaine provides effective 
  
anesthesia and superior postoperative analgesia when used in forearm 
IVRA.  
8.  Comparing the effectiveness of modified forearm and conventional 
IVRA for reduction of distal forearm fractures in children. Journal of 
paediatric orthopaedics 28(4) : 410-416. June 2008. This study was 
conducted in 62 patients. The modified forearm Intra Venous Regional 
Anesthesia, procedure is acceptable alternative for the relief of pain that 
usually accompanies the manipulation and reduction of forearm 
fractures. 
 
9.  Meperidine in forearm IVRA Anesthesia Analgesia 1999; 88:831 
They have concluded that prolonged analgesia is due to local effects. The 
dose of Local anesthetics required for successful blockade using the 
forearm method is approximately 50% less than used in conventional 
technique. 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
This is a prospective, randomized comparative study conducted at 
Govt. Rajaji Hospital attached to Madurai Medical College.  
After approval by the ethical committee 60 patients of ASA grade I 
and II age between 15-50 years who came for hand surgeries which lasted 
for less than 45 minutes were included in the study. 
Patients with history of allergy to local anesthetics, sickle cell disease, 
raynaud’s disease, scleroderma, local infection, paget’s disease and patients 
with inadequate starvation <6 hours were excluded from this study. 
Preanesthetic evaluation was done.   
No patients were premeditated. Resuscitation equipment and drugs 
were kept ready. Pulse rate, Blood Pressure and Oxygen saturation were 
estimated continuously. 18G iv cannula was started in the non operative 
hand.  
Upperarm Intravenous Regional Anesthesia group (control group): 
 A 22G cannula was placed intravenously in the arm to be 
anesthetized. The double tourniquet was applied on the arm with generous 
layers of padding, ensuring that no wrinkles are formed and the tourniquet 
edges do not touch the skin. The arm was exsanguinated by using Esmarch 
bandage. If this was impossible, exsanguination was achieved by elevating 
the arm for 2-3 minutes while compressing the axillary artery. Tourniquet 
  
pressure of systolic plus 100mmHg was used. Circulatory isolation of the 
operative arm was confirmed by inspection of the hand and by absence of 
the radial pulse. A standard volume of 40ml of 0.5% Lignocaine containing 
200mg was used. 
Forearm Intravenous Regional Anesthesia group (study group): 
 Here the double tourniquet was positioned 1cm below the medial 
epicondyle. A standard volume of 20ml of 0.5% Lignocaine containing 
100mg of Lignocaine was used. 
 IVRA solution was administrated slowly via the cannula for 3 
minutes. The distal tourniquet was used as a safety measure, it was not 
inflated in any patient. 
 After injection of the IVRA solution, sensory block was assessed at 
thenar eminence (median nerve), hypothenar eminence (ulnar nerve) and 
first web space (radial nerve) at 30 seconds interval. The cuff was not 
deflated until 20 minutes after local anesthesia injection even if surgery was 
completed before 20 minutes. Cuff deflation was performed in cycles of 
deflation/inflation times of less than 10 seconds until the patient no longer 
exhibits signs of systemic toxicity. Patients were observed 60 minutes after 
surgery. 
    Sensory regression was assessed at the same sites at 30 seconds 
interval, after tourniquet deflation. Postoperatively, pain was assessed by 
  
using verbal analog pain scale between ‘0’ and ‘10’ with ‘0’ representing no 
pain and 10 representing the worst imaginable pain. 
Intraoperatively the following parameters were noted: 
Pulse rate, blood pressure, Oxygen saturation were monitored regularly 
at frequent intervals 
¾ Sensory and Motor blockade onset times. 
¾ Duration of surgery 
¾ Mean tourniquet time  
¾ Mean Tourniquet Pressure 
¾ Modified Lovett’s Scoring to assess the motor power. 
6 Good 
3 – 5 Fair 
1 – 2 Poor 
0 No contraction 
 
¾ Intraoperative verbal analog scale 
¾ Verbal analog scale after deflation 
¾ Field of surgery 
¾ Sensory and motor blockade regression time  
 
  
 
  
RESULTS AND OBSERVATIONS 
 
FOREARM IVRA : Cases given  Intravenous Regional  Anesthesia using a 
forearm tourniquet 
UPPERARM IVRA : Cases given  intravenous regional  Anesthesia using 
a upperarm tourniquet 
 
TABLE 1: Age distribution 
Forearm IVRA Upperarm IVRA Age group 
No. % No. % 
Upto 20 years - - - - 
21-30 15 50 13 43.3 
31-40 12 40 11 36.7 
Above 40 years 3 10 6 20 
Total 30 100 30 100 
Mean 
S.D. 
30years 
8.5 years 
33.1 years 
7.5 years 
‘p’ 0.0527 
Not Significant 
 
The difference between the group with respect to age is not 
statistically significant. Hence the groups are comparable with respect to 
age. 
  
TABLE  2: Sex distribution 
Forearm IVRA Upperarm IVRA  
No. % No. % 
Males 18 60 19 63.3 
Females 12 40 11 36.7 
Total 30 100 30 100 
‘p’ 1.0 
Not significant 
 
The difference between the groups with respect to sex is not 
statiscally significant. Hence the groups were comparable with respect to 
sex. 
TABLE  3: Weight 
 
Weight 
 
Forearm IVRA  
 
Upperarm IVRA 
Mean 
S.D. 
51.1 
4.4 
50.6 
3.7 
‘p’ 0.9108 
Not significant 
The difference between the groups with respect to weight is not 
statistically significant. Hence the groups were comparable with respect to 
weight. 
  
 
 
 
TABLE  4: Mean Arterial Pressure during the procedure 
  
Forearm IVRA Upperarm IVRA  
MEAN ARTERIAL  
PRESSURE 
 
Mean S.D. Mean S.D. 
 
‘p’ 
 
At 1 minute 
 
At 5 minutes 
 
Change in 5 minutes 
 
106.53 
 
104.34 
 
1.53 
 
6.7 
 
6.3 
 
4.34 
 
104.5 
 
102.8 
 
1.43 
 
4.7 
 
5.3 
 
2.37 
 
0.8273 
Not significant 
0.9272 
Not significant 
0.7234 
Not significant 
 
 
 
 
 
 
 
  
 
 
 
Table 5 : Pulse Rate during the procedure 
Forearm IVRA Upperarm 
IVRA 
 
Pulse Rate 
Mean S.D. Mean S.D. 
 
‘p’ 
 
At 1 minute 
 
At 5 minutes 
 
Change in 5 minutes 
 
81.5 
 
80.5 
 
0.99 
 
5.6 
 
5.9 
 
3.19 
 
81.9 
 
82.5 
 
0.73 
 
4.6 
 
4.9 
 
3.19 
 
0.7113 
Not significant 
0.6326 
Not significant 
0.7414 
Not significant 
 
The difference between the groups with respect to the mean arterial 
pressure and pulse rate at 5 minutes interval intraoperatively was not 
statistically significant. 
  
 
 
 
 
TABLE  6 : Mean Arterial Pressure after deflation 
  
Forearm IVRA Upperarm IVRA MAP AFTER 
DEFLATION Mean S.D. Mean S.D. 
 
‘p’ 
 
At 1 minute 
 
At 5 minutes 
 
Change in 5 minutes 
 
105.7 
 
104.3 
 
-1.33 
 
6.8 
 
7.7 
 
6.8 
 
105.9 
 
105 
 
-0.87 
 
6.0 
 
7.3 
 
4.5 
 
0.9274 
Not significant 
 0.7417 
Not significant 
0.9662 
Not significant 
  
 
 
TABLE  7 : Pulse Rate  after deflation 
Forearm IVRA Upperarm IVRA  Pulse Rate 
After deflation Mean S.D. Mean S.D. 
 
‘p’ 
 
At 1 minute 
 
At 5 minutes 
 
Change in 5 minutes 
 
83.3 
 
84.23 
 
0.98 
 
5.1 
 
4.81 
 
4.24 
 
83.5 
 
84.13 
 
0.63 
 
5.2 
 
4.71 
 
2.24 
 
0.8994 
Not significant 
0.7758 
Not significant 
0.5582 
Not significant 
 
The difference between the groups with groups with respect to the 
mean arterial pressure and pulse rate at 5 minutes interval after cuff 
deflation was not statistically significant. 
 
 
 
 
 
 
 
  
 
 
 
TABLE  8: Tourniquet Pressure 
 
 
Tourniquet Pressure 
 
 
Forearm IVRA 
 
Upperarm IVRA 
Mean 
S.D. 
212 
9.25 
218 
8.45 
‘p’ 0.9373 
Not significant 
 
The difference between the groups with respect to the Tourniquet 
pressure used is not statistically significantly. Hence the groups were 
comparable with respect to the tourniquet pressure.
  
 
 
Table 9: Onset time 
Forearm IVRA Upperarm IVRA  
Onset time Mean S.D. Mean S.D. 
 
‘p’ 
Sensory Block 2.77 0.68 2.7 0.75 0.6348 
Not Significant 
Motor Block 5.93 1.38 7.17 1.53 0.0025 
Significant 
 
The sensory block onset time in the study group and control group 
were 2.77 minutes and 2.7 minutes respectively. The difference in the 
sensory block onset time was not statistically significant. 
The motor block onset time in the study group and control group were 
5.93 minutes and 1.53 minutes respectively, the difference of which is 
statistically significant. 
 
 
 
 
 
 
  
 
 
Table 10: Modified Lovett’s Score  
Forearm IVRA Upperarm IVRA  
Modified Lovett’s Score No. % No. % 
0 - - 3 10 
1 - - 10 26.7 
2 - - 11 36.7 
3 9 30 8 26.7 
4 13 43.8 - - 
5 8 26.7 - - 
Total 30 100 30 100 
Mean 
S.D. 
3.97 
0.76 
1.8 
0.96 
‘p’ 0.0001 
Significant 
 
The mean Modified Lovett’s scoring for the motor power grading of 
the study and control group were 3.97 and 1.8 respectively, the difference of 
which was statistically significant. 
  
 
 
 
 
TABLE  11: Tourniquet Time 
 
 
Tourniquet Time 
 
 
Forearm IVRA 
 
Upperarm 
IVRA 
Mean 
S.D. 
32.47 
2.33 
32.37 
2.16 
‘p’ 0.9326 
Not significant 
 
The mean Tourniquet time of the study group and control group were 
32.47 and 32.37 minutes respectively, the difference of which is statistically 
not significant. 
 
 
 
 
 
 
  
 
 
 
 
TABLE  12:  Duration of Surgery 
 
 
Duration of Surgery  
 
Forearm IVRA 
 
Upperarm IVRA 
Mean 
S.D. 
37.5 
2.45 
37.43 
2.86 
‘p’ 0.6051 
Not significant 
 
The mean duration of surgery in the study group and control group 
were 37.5 and 37.43 minutes, the difference of which is not statistically 
significant. 
 
 
 
 
 
 
  
 
Table 13    : VAS 
Forearm IVRA Upperarm IVRA 
VAS Mean S.D. Mean S.D. 
 
‘p’ 
At 10 minutes 0.067 0.254 0 0 0.1538 
Not Significant 
At 20 minutes 0.267 0.583 0.033 0.183 0.0639 
Not Significant 
At 30 minutes  0.567 0.858 0.233 0.504 0.112 
Not significant 
At 10 minutes 
after deflation 
0.3 0.466 1.5 0.938 0.0001 
Significant 
At 30 minutes 
after deflation 
1.0 0.947 6.17 0.834 0.0001 
Significant 
At 60 minutes 
after deflation 
2.9 1.21 8.03 0.81 0.0001 
Significant 
 
The difference in the mean VAS during the procedure was not 
statistically significant. 
The difference in the mean VAS after cuff deflation at 10, 30, 60 
minutes were statistically significant. 
  
 
 
 
TABLE  14: Field of Surgery 
 
Forearm IVRA Upperarm IVRA  
Field of Surgery No. % No. % 
Excellent 17 56.7 21 70 
Good 11 36.7 8 26.7 
Oozing (+) 2 6.7 1 3.3 
Total 30 100 30 100 
 
The field of surgery in the study group was excellent in the study 
group was excellent in 56.7%, good in 36.7%, and oozing was present in 
6.7%. in the control group it was excellent in 70%, good in 26.7% and 
oozing was present in 33% of the cases. 
  
 
 
 
Table 15: Regression Time 
 
Forearm IVRA Upperarm IVRA 
Recovery Time Mean S.D. Mean S.D. 
 
‘p’ 
Sensory Block 8.97 2.33 2.7 1.06 0.0001 
 Significant 
Motor Block 7.87 2.03 8.43 1.22 0.3862 
Not Significant 
 
Sensory block regression time in the study group and control group 
were 8.97 minutes and 1.06 minutes respectively, the difference of which is 
statistically significant. Motor block regression time in the study and control 
group were 7.87 and 1.22 minutes, the difference of which is not statistically 
significant.
  
 
 
Statistical Tools  
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002).  
 Using this software, range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between 
quantitative variables. A 'p' value less than 0.05 is taken to denote 
significant relationship. 
 
 
 
 
 
 
 
 
  
DISCUSSION 
Intravenous regional anesthesia uses local anesthetics administered to 
one particular limb occluding the arm proximally, to provide conduction 
blockade. It must be safe not threatening or unpleasant to the patient. It 
allows adequate surgical access to the operative site and cause as little 
disturbance as possible to the internal homeostatic mechanisms. 
          Intravenous regional anesthesia has many advantages. It is simple, 
reliable with rapid onset and recovery. Despite these advantages, 
conventional IVRA has some limitations, including the potential for local 
anesthetic toxicity and lack of postoperative analgesia. It also has potential 
toxic effects which can occur despite an adequate tourniquet time. In this 
study, we attempted to eliminate these disadvantages by using a forearm 
tourniquet. 
COMPARISON OF RESULTS: 
          In this study, the Forearm IVRA group and upperarm IVRA group 
patients were comparable in respect to age, sex, weight, tourniquet pressure, 
tourniquet time and duration of surgery. 
         The onset of sensory blockade was similar in both groups. It was 2.77 
and 2.7 minutes respectively in the study and control group respectively. 
The onset of motor blockade was delayed in the study group. It was 5.93 
and 1.53 minutes in the study and control group respectively. This is 
  
contrary to the findings of Scott S. Reuban et al, where the motor block 
onset time were similar in both groups. 
     The Modified Lovett’s score in the Forearm IVRA group was 3.97 which 
comes under the grading of motor power – fair category. Whereas the 
Modified Lovette’s score in the upperarm IVRA group was 1.8which comes 
under the poor category. The ‘p’value  being 0.0001 which is highly 
significant. This results correlates with Nazim Karelezhi et al. they conclude 
that Forearm IVRA allows for the preservation of some motor function of 
the long flexors and extensors of the wrist and hand which is useful in 
certain operations such as tenolysis. 
     Tourniquet tolerance was good in both the groups. Intraoperative VAS 
was less than 1 in all patients. Two patients in the study group and one in 
the control group had tourniquet pain. The reason for this is the duration 
exceeded 40 minutes. So tourniquet was released and was supplemented by 
metacarpal block. 
     The motor block regression time was 7.81 and 8.43 minutes in the study 
and control group respectively. The sensory block regression time was 8.97 
and 2.7 minutes in the study and control group. The ‘p’ value being 0.0001 
which statistically significant. The recovery of pain sensation is rapid in the 
upperarm IVRA group after tourniquet deflation. Subsequent hemostasis 
and wound closure was difficult to achieve. So three cases were 
  
supplemented using wound infiltration. No supplementation was used in the 
study group. 
     Intraoperatively the surgeons were comfortable with the field of surgery. 
Oozing was observed in 2 cases in the study group and 1 case in the control 
group, which was not cumbersome and no toxic reactions were observed. 
     VAS was least in the study group in the postoperative period 60 minutes 
after tourniquet deflation. The ‘p’ value being 0.000l which was statistically 
significant. 
     Forearm IVRA not only increases the safety margin of the technique but 
also provides enhanced postoperative analgesia. According to the study by 
Coleman et al who studied the quantitative comparison of leakage under the 
tourniquet in Forearm versus conventional IVRA the reason for this 
enhanced analgesic action may be an increased binding of analgesics to 
local tissues during Forearm IVRA. 
     In addition, a Forearm tourniquet can be tolerated for a longer period of 
time and is consistently rated less painful compared with the upperarm 
tourniquet as concluded by Edward et al. considering all the above said 
factors IVRA using a forearm tourniquet allows the dose of local anesthetic 
to be decreased by upto 50%without affecting the quality of analgesia, with 
improved duration of postoperative analgesia. 
 
  
SUMMARY 
 This prospective, randomized comparative study of Intravenous 
Regional Anesthesia using a forearm tourniquet versus upperarm 
tourniquet was conducted a thirty patients in each group at Govt. Rajaji 
Hospital. 
 Intravenous Regional Anesthesia using forearm tourniquet 
increases the margin of safety of the technique by allowing fifty 
percent reduction in the dose of Lignocaine in comparison with the 
conventional technique.  Therefore, this approach reduces the risk of 
local anesthetic toxicity in the event of tourniquet failure. 
 The sensory block regression time was 8.97 and 2.7 minutes in 
the study group and control group respectively, the different of which 
was statistically significant.  The recovery of pain sensation was rapid 
in the upperarm IVRA group after tourniquet deflation.  Subsequent 
hemostasis and wound closure will be difficult.  So the block must be 
supplement with infiltration or metacarpal block.  Because IVRA using 
forearm tourniquet provides prolonged sensory blockade it reduces or 
eliminates the need to supplement the block. 
 The modified Lovett’s score of grading of motor power was 3.97 
and 1.8 in the study and control group respectively.  Usage of forearm 
  
tourniquet allows for the preservation of some motor function of the 
long floors and extensors of the wrist and hand which is useful in 
certain operations like tenolysis and tendon repair, where complete 
motor blockade is not needed. 
 Patients in both the groups had adequate intraoperative analgesia.  
The difference in the mean VAS at 10, 20 and 30 minutes was not 
statistically significant in both the groups.  The mean VAS at 60 
minutes after tourniquet deflation in the study and control were 2.9 and 
8.03 respectively the difference of which was statistically significant.  
Thus Intra Venous Regional anesthesia using forearm tourniquet 
provides prolonged post operative analgesia. 
 
 
 
 
 
 
 
 
 
  
 
 
 
CONCLUSION 
 
      Intra Venous Regional Anesthesia using forearm tourniquet 
in comparison with upperarm tourniquet, 
1. Has increased margin of safety, by allowing fifty percent 
reduction in the drug dosage. 
2. Provides, adequate intraoperative analgesia 
3. Offers, longer duration of sensory blockade after 
tourniquet deflation. 
4. Provides, prolonged post operative analgesia. 
5. Provides, lesser degree of motor blockade which is useful 
in certain tendon surgeries.  
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PROFORMA 
Name  :    Age  :   Sex  : 
Weight :    IP/OPNo. :   Date: 
Diagnosis : 
Procedure : 
Anesthetic Technique  : 
Drug & Dose  : 
Time of inflation  :    Time of deflation : 
Tourniquet pressure : 
Sensory blockade onset time :   Motor blockade onset time : 
Vital signs  5 min 10 min 15 min 20 min 30 min 
Pulse rate      
Blood 
pressure 
     
SPO2      
 
Vital signs after 
deflation 
 5 min 10 min 15 min 20 min 30 min 
Pulse rate      
Blood pressure      
SPO2      
 
 
  
Modified Lovett Rating Scale for motor power : 
6 Good 
3 – 5 Fair 
1 – 2 Poor 
0 No contraction 
 
VAS  during 
surgery 
 0 min 10 min 20 min 30 min 
     
 
VAS  after 
deflation 
 0 min 10 min 20 min 30 min 
     
 
Blood Less filed of Surgery : 
 Excellent   Good   Oozing + 
Duration of Surgery : 
Tourniquet time  : 
Duration of sensory blockade after deflation  : 
Duration of motor blockade after cuff deflation  : 
Complications   : 
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SENSORY BLOCK REGRESSION TIME
Mean
 INTRAVENOUS REGIONAL ANAESTHESIA USING A UPPERARM VERSUS UPPER ARM TOURNIQUET
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1 Moorthy 40 M 43226 55 Rt Ganglion wrist Excision 70 110/70 72 110/70 210 4 8
2 Krishnan 42 M 44126 48 Rt Ganglion wrist Excision 82 110/70 85 110/70 210 3 7
3 Sonai 30 M 46144 53 Lt Ganglion wrist Excision 85 100/70 88 110/70 200 2 6
4 Annamalai 42 M 53772 48 Rt Palm crush Injury Repair 88 110/70 85 110/70 210 3 7
5 Kollan 23 M 63112 50 Laceration fore arm Suturing 80 130/80 82 130/70 220 4 6
6 Ponmani 31 F 62606 48 Dequervan's Disease Tenolysis 78 120/70 75 120/70 220 2 5
7 Devika 26 F 63120 42 PBC Lt Index Repair 81 110/70 84 110/70 210 2 8
8 Shanmugam 36 M 65602 51 Granulom Rt Index Excision 86 120/70 88 120/70 220 3 9
9 Pongodi 40 F 68906 48 FR granuloma Rt Index Excision 81 130/80 83 130/80 230 2 10
10 Chitra 21 F 101762 52 Ganglion Lt wrist Excision 81 110/70 84 110/70 210 2 9
11 Kasinathan 23 M 101769 48 B Granuloma DorsumLt han Excision 88 120/70 85 110/70 220 2 8
12 Povizhi 28 F 100278 52 Cut injury F4 Rt Repair 78 110/70 75 110/70 200 3 9
13 Rajeshwari 43 F 100215 55 PIBC Rt Middle finger Release 76 120/70 78 120/70 210 2 10
14 Dishab Begum 40 F 102062 56 Rt Ganglion wrist Excision 82 110/70 88 110/70 200 4 7
15 Pothumani 43 M 21626 48 Lt Dequervan's Disease Tenolysis 90 110/70 91 120/70 230 3 7
16 Lakshmi 40 F 21292 52 Rt Dequervan's Disease Tenolysis 78 110/70 75 110/70 210 2 8
17 Karuppasamy 26 M 26111 51 PBC F3 Rt Release 72 120/70 78 120/70 210 2 7
18 Sethupathi 33 M 68266 52 Ganglion Lt Palm Excision 82 110/70 85 110/70 200 3 8
19 Seetharaman 21 M 68772 55 Ganglion Rt dorsum hand Excision 84 120/71 86 120/70 220 3 7
20 Mayakal 40 M 38412 45 Left Middle finger cut injury Repair 82 120/72 84 120/70 220 2 10
21 Noorjahan 30 F 76128 48 Ganglion Lt FA Excision 86 110/70 88 110/70 210 2 6
22 Sambu 41 M 77161 50 Ganglion Rt wrist Excision 84 110/70 80 110/70 220 2 5
23 Prabhakar 28 M 350612 55 ETI Repair 90 110/70 88 110/70 200 3 7
24 Prabhu 36 M 371126 45 Ganglion Lt Excision 90 110/70 85 110/70 210 3 7
25 Sudhakar 31 M 77891 50 Cut Injury Rt Index Repair 76 110/70 80 120/70 210 2 5
26 Chandra 28 F 78120 55 Ext. pollicis tendon cut Repair 88 110/70 85 120/70 220 2 6
27 Selvi 22 F 81011 45 Ganglion Lt Excision 75 110/70 78 120/70 200 4 5
28 Pandiyan 39 M 178061 56 Ganglion Rt Excision 72 120/70 75 120/70 210 3 5
29 Kaleswaran 28 M 81606 55 Stitch granuloma Lt Index Excision 80 120/70 82 120/70 210 4 7
30 Muthu 41 M 82101 49 Ganglion Rt Excision 88 110/70 83 110/70 210 3 6
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3 32 35 0 0 0 Excellent 4 7 0 6 8 82 110/70 85 110/70 Nil
2 30 38 0 0 0 Excellent 2 10 0 7 9 80 110/70 81 110/70 Nil
3 35 40 0 0 0 Excellent 2 8 1 8 8 78 110/70 78 100/70 Nil
2 32 38 0 0 0 Good 4 9 2 7 9 76 110/70 78 100/70 Nil
1 30 35 0 1 1 Excellent 4 7 1 5 8 80 130/70 78 130/70 Nil
0 35 40 0 0 1 Excellent 2 10 2 6 9 90 120/70 91 110/70 Nil
3 34 38 0 0 0 Good 4 8 0 7 7 88 110/70 86 120/70 Nil
2 32 36 0 0 0 Excellent 2 7 1 6 8 96 120/70 95 120/70 Nil
1 30 35 0 0 0 Excellent 2 6 2 7 9 90 130/80 92 130/70 Nil
2 35 45 0 0 1 Excellent 4 8 1 6 8 78 110/70 79 110/70 Nil
3 35 40 0 0 0 Good 3 8 2 7 8 76 120/70 80 120/70 Nil
2 30 35 0 0 1 Excellent 3 9 2 5 7 90 110/70 91 120/70 Nil
3 31 35 0 0 0 Good 2 10 1 6 9 85 120/70 84 120/70 Nil
3 32 35 0 0 0 Excellent 4 10 2 7 9 86 110/70 88 110/70 Nil
1 30 35 0 0 1 Excellent 3 9 1 5 7 84 120/70 86 120/70 Nil
2 35 40 0 0 0 Good 2 10 2 6 8 88 110/70 90 110/70 Nil
1 32 38 0 0 0 Excellent 4 9 0 6 7 82 120/70 84 120/70 Nil
2 31 36 0 0 0 Good 2 8 3 5 8 82 110/70 86 110/70 Nil
1 32 38 0 0 0 Excellent 3 9 2 7 7 80 120/70 84 120/70 Nil
1 35 40 0 0 0 Good 1 10 1 6 9 82 110/70 84 110/70 Nil
3 30 35 0 0 0 Excellent 4 10 2 5 7 78 120/70 76 120/70 Nil
0 32 35 0 0 0 Good 1 7 3 6 8 88 110/70 89 110/70 Nil
1 33 38 0 0 2 Excellent 4 8 1 7 9 80 130/80 82 120/70 Nil
2 30 35 0 0 0 Excellent 2 7 2 7 9 86 110/70 85 110/70 Nil
3 31 35 0 0 0 Excellent 2 8 3 6 8 78 110/70 80 110/70 Nil
0 32 35 0 0 0 Excellent 4 10 0 5 7 82 110/70 80 110/70 Nil
1 35 40 0 0 0 Excellent 2 9 1 6 7 86 120/70 84 120/70 Nil
2 38 45 0 0 0 Excellent 1 7 2 7 8 88 120/70 84 120/70 Nil
2 30 35 0 0 0 Oozing(+) 2 8 3 5 9 90 120/70 86 120/70 Nil
2 32 38 0 0 0 Excellent 2 7 2 6 7 76 110/70 78 110/70 Nil

